Arnaud Loriers, chief commercial officer of the Belgian-based biotech company KiOmed, discusses KioMedine, a patented, mushroom-derived, single-injection technology designed for patients with refractory knee osteoarthritis, in an interview with SmartTRAK at the 22nd European Society of Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA) Congress in Prague, held May 20-22, 2026.
Loriers highlights how this innovative, long-lasting treatment helps delay total knee arthroplasty—particularly for younger, active individuals and high-BMI populations who lack effective alternatives. Currently CE-marked and available in 25 countries with over 65,000 patients treated, KiOmed is rapidly expanding its global footprint with upcoming launches in Great Britain, Vietnam, and China, while actively laying the regulatory groundwork to enter the US market.
To listen to the full interview, click on the following video (05:04 min). A link to download the complete interview transcript is also provided below.
Interview Transcript
SmartTRAK: Hi, this is Sharon O'Reilly, and I'm at the 2026 ESSKA Conference in Prague, and I'm here with Arnaud Loriers from KiOmed with a very interesting technology. Arnaud, tell me a little bit about your technology and company.
Arnaud Loriers: Hi. My name is Arnaud Loriers, chief commercial officer. I'm here to present KioMedine. KioMedine is a product extract from the mushroom. It's an innovation built by the University of Liége and a company called KitoZyme, which we have decided to put KiOMed as a spinoff for medical applications.
This product is helping patients with refractory knee osteoarthritis to get a better life. This product helps with ...
Interested in the science behind KiOmed's novel mushroom-derived, single-injection OA treatment? Download the complete transcript of SmartTRAK CEO Sharon O'Reilly's exclusive interview with KiOmed Pharma Chief Commercial Officer Arnaud Loriers by clicking the button below.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to mkt experts for inquiries and advisory services. If you would like a demo of what SmartTRAK offers and how we can help increase efficiency, improve productivity and reduce costs for your company, just click here.